Biogen (XTER:IDP) Accumulated Depreciation : €-2,537 Mil (As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Biogen Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Biogen's quarterly accumulated depreciation increased from Sep. 2024 (€-2,347 Mil) to Dec. 2024 (€-2,551 Mil) but then stayed the same from Dec. 2024 (€-2,551 Mil) to Mar. 2025 (€-2,537 Mil).

Biogen's annual accumulated depreciation increased from Dec. 2022 (€-2,044 Mil) to Dec. 2023 (€-2,203 Mil) and increased from Dec. 2023 (€-2,203 Mil) to Dec. 2024 (€-2,551 Mil).

Biogen Accumulated Depreciation Historical Data

The historical data trend for Biogen's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Accumulated Depreciation Chart

Biogen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-1,465.05

-1,775.84

-2,044.42

-2,203.09

-2,550.61

Biogen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-2,270.74	-2,357.25	-2,346.56	-2,550.61	-2,537.18

Biogen Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Biogen Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Biogen's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XTER:IDP) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany BIIB:Chile BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines